Eye On Expanding Surgical Systems That Lengthen Treatment Intervals in nAMD and DME

0.75 CME
0.75 CME WITH ABO CONTINUING CERTIFICATION
45 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Eye On Expanding Surgical Systems That Lengthen Treatment Intervals in nAMD and DME

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Genentech, a member of the Roche Group.


Activity Description

Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the management paradigm for patients with retinal vascular diseases, yet there is still an unmet need to address treatment burden and loss of patient adherence due to dosing schedules. For patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), there is ongoing evaluation of gene therapy and sustained delivery devices, as they provide the potential to extend treatment intervals while maintaining visual acuity. These advances in treatment delivery require unique surgical approaches for optimal efficacy outcomes and safety. In this CME activity, experts in the field review emerging surgical delivery systems that allow for the management of nAMD and DME over an extended period of time as well as evaluate novel surgical techniques and best practices for reducing potential complications.


Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe emerging surgical delivery systems that allow for the treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME) over an extended period of time.
  • Evaluate novel surgical techniques and best practices that can reduce the potential for complications when implanting and refilling the port delivery system with ranibizumab.

Faculty

Carl C. Awh, MD
President, Tennessee Retina
President, the American Society of Retina Specialists
Nashville, TN

Jordan M. Graff, MD, FACS, FABO
Surgeon & Partner, BDP Eye Center – Retina Division
American Vision Partners (AVP) Medical Executive Team
Clinical Assistant Professor of Ophthalmology
University of Arizona College of Medicine – Phoenix
Clinical Assistant Professor
Creighton University
Phoenix, AZ


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, November 22, 2021, to November 21, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Faculty members report the following relationship(s)

Carl C. Awh, MD
Consulting Fee: Bausch + Lomb, Genentech, Katalyst Surgical, Volk
Contracted Research: Adverum, Apellis, Genentech, GlaxoSmithKline, Hoffman-LaRoche, Kodiak, Merck, Ophthotech, PanOptica, Regeneron, Stealth BioTherapeutics
Ownership Interest: ArcticDx, Katalyst
Royalty: Bausch + Lomb, Katalyst Surgical

Jordan M. Graff, MD, FACS, FABO
Consulting Fee: Genentech/Roche
Speakers Bureau: Genentech/Roche
Contracted Research: Genentech, Novartis, Regeneron

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com